

BIO RAD LABORATORIES INC  
 Form 4  
 September 13, 2016

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL  
 OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 SCHWARTZ NORMAN D

2. Issuer Name and Ticker or Trading Symbol  
 BIO RAD LABORATORIES INC  
 [BIO, BIOB]

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 Chairman, President, and CEO

(Last) (First) (Middle)  
 C/O BIO-RAD LABORATORIES,  
 INC., 1000 ALFRED NOBEL  
 DRIVE  
 (Street)

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 09/10/2016

HERCULES, CA 94547  
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(D)	Price
Bio-Rad A Common Stock					411,252	D	
Bio-Rad B Common Stock	09/10/2016		M		2,000 (1)	A	\$ 0
Bio-Rad B Common Stock	09/10/2016		F		1,044	D	\$ 159.8
					198,719	D	

Edgar Filing: BIO RAD LABORATORIES INC - Form 4

Bio-Rad B Common Stock	09/11/2016	M	<u>5,800</u> (1)	A	\$ 0	204,519	D	
Bio-Rad B Common Stock	09/11/2016	F	3,027	D	\$ 159.8	201,492	D	
Bio-Rad B Common Stock	09/12/2016	M	<u>2,617</u> (1)	A	\$ 0	204,109	D	
Bio-Rad B Common Stock	09/12/2016	F	1,366	D	\$ 159.32	202,743	D	
Bio-Rad B Common Stock						12,586	I	By Spouse (2)
Bio-Rad B Common Stock						4,060,054	I	By Blue Raven Partners, L.P. (3)
Bio-Rad B Common Stock						13,726	I	By DANSA Partnership (4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Pr Deriv Secur (Instr	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	\$ 0 (5)	09/10/2016		M	2,000	(6)	(6)	Bio-Rad B Common	2,000

Restricted Stock Units	Cost	Acquisition Date	Relationship	Quantity	Footnote	Footnote	Class	Quantity	Value
Restricted Stock Units	\$ 0 <sup>(5)</sup>	09/11/2016	M	2,600	<sup>(7)</sup>	<sup>(7)</sup>	Bio-Rad B Common Stock	2,600	\$
Restricted Stock Units	\$ 0 <sup>(5)</sup>	09/11/2016	M	3,200	<sup>(8)</sup>	<sup>(8)</sup>	Bio-Rad B Common Stock	3,200	\$
Restricted Stock Units	\$ 0 <sup>(5)</sup>	09/12/2016	M	2,617	<sup>(9)</sup>	<sup>(9)</sup>	Bio-Rad B Common Stock	2,617	\$

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SCHWARTZ NORMAN D C/O BIO-RAD LABORATORIES, INC. 1000 ALFRED NOBEL DRIVE HERCULES, CA 94547	X	X	Chairman, President, and CEO	

## Signatures

Norman D. Schwartz                      09/13/2016

<sup>\_\_</sup>Signature of Reporting Person                      Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares of Class B common stock acquired on the vesting of restricted stock units.
- (2) The reporting person disclaims beneficial ownership of these shares.
- (3) The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- (4) The shares are held by a limited partnership of which the reporting person is a limited partner.
- (5) Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class B common stock.
- (6) The restricted stock units vest in five equal annual installments beginning September 10, 2015.
- (7) The restricted stock units vest in five equal annual installments beginning September 11, 2014.
- (8) The restricted stock units vest in five equal annual installments beginning September 11, 2016.
- (9) The restricted stock units vest in five equal annual installments beginning September 12, 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.